Search clinical trials for: EGFR/HER2 overexpression/amplification

Total 4242 results

Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
Shenzhen Second People's Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer (EGFRCART)

Metastatic Colorectal Cancer

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy (DIAMOND)

Metastatic Breast Cancer

Italy
Crimson Biopharm Inc.

Not yet recruiting

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

Glioblastoma
Universitair Ziekenhuis Brussel

Recruiting

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

Carcinoma | Receptor, ErbB-2

Belgium
University of Milan

Recruiting

Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD

COPD | Dyspnea | Argininemia

Italy
Peking University

Unknown

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Esophageal Squamous Cell Carcinoma

China
University of Virginia

Terminated

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Breast Cancer Female | Leptomeningeal Metastases

United States
Jules Bordet Institute

Completed

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients (IJBMNZrT003)

Breast Neoplasms | Secondary | HER2 Positive Carcinoma of Breast

Belgium
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
The Netherlands Cancer Institute
Roche Pharma AG; AstraZeneca

Terminated

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC (TRAEMOS)

Carcinoma, Non-Small-Cell Lung

Netherlands
Symphogen A/S

Withdrawn

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Metastatic Colorectal Cancer
Sichuan University

Recruiting

Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Pleural Effusion, Malignant | Peritoneal Carcinoma Metastatic

China
Hunan Province Tumor Hospital

Recruiting

Efficacy of Osimertinib in Patients With Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Assiut University

Unknown

Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital

Antiviral Drug
Allergan

Terminated

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

Rash | Non-small-Cell Lung Cancer

United States
Samsung Medical Center

Completed

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Metastatic Breast Cancer

Korea, Republic of
Shanghai General Hospital, Shanghai Jiao Tong University...
NanoMab Technology (UK) Limited

Recruiting

HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

Breast Cancer | Radiotoxicity

China
Samsung Medical Center

Unknown

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
The University of Texas Health Science Center at...
University of Pittsburgh

Completed

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma

United States
Carisma Therapeutics Inc

Recruiting

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

HER2-positive

United States
Dana-Farber Cancer Institute
Addario Lung Cancer Medical Institute

Active, not recruiting

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT)

Lung Cancer

United States
National Cancer Center, Korea
Korean Cancer Study Group

Recruiting

EGFR-targeted Therapy for Gastric Cancer

Adenocarcinoma of the Stomach

Korea, Republic of
Jazz Pharmaceuticals
ALX Oncology Inc.

Active, not recruiting

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

HER2-expressing Cancers

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene Mutation

United States
Molecular Templates, Inc.

Terminated

Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)

HER2-positive Solid Cancers

United States, Australia, New Zealand
H. Kim Lyerly
Susan G. Komen Breast Cancer Foundation

Completed

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

HER2+ Cancer

United States
University of Pittsburgh
National Cancer Institute (NCI)

Terminated

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and Neck

United States
Boehringer Ingelheim

Terminated

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Neoplasms

United States, Taiwan
Sinocelltech Ltd.

Unknown

SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Second Military Medical University

Unknown

Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis

Gastric Cancer | Liver Metastasis

China
Korea University Guro Hospital
Chong Kun Dang Pharmaceutical Corp.

Active, not recruiting

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Sun Yat-sen University

Unknown

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

Non-Small Cell Lung Cancer

China
ETOP IBCSG Partners Foundation
AstraZeneca

Terminated

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
AstraZeneca

Completed

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL)

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Canada, Korea, Republic of, Taiwan
Peking University

Not yet recruiting

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Esophageal Squamous Cell Carcinoma

China
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

HER2-positive Breast Cancer | HER2-positive Biliary Tract Cancer | HER2-Positive Salivary Gland Carcinomas | HER2-Positive Advanced Solid Tumor

China, Australia, United States
Kaohsiung Veterans General Hospital.

Completed

Effects of the Eefooton on eGFR and QoL in Chronic Kidney Disease Patients.

Chronic Kidney Diseases

Taiwan
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR)

Brain Tumor, Recurrent | Brain Tumor, Refractory

United States
Sierra Oncology, Inc.

Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

United States
Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
NKGen Biotech, Inc.

Withdrawn

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | EGF-R Positive Non-Small... and other conditions
Il Yeong Park, Ph.D.

Unknown

Anticancer Activity of Nicotinamide on Lung Cancer

Non-Small-Cell Lung Carcinoma

Korea, Republic of
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Tongji Hospital

Recruiting

68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients

HER2-Positive Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Nonsmall Cell Lung Cancer | EGFR Gene Mutation
University of Pennsylvania
Gilead Sciences

Recruiting

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

Glioblastoma

United States
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC

EGFR Gene Mutation

Korea, Republic of
Peking University
RemeGen Co., Ltd.

Recruiting

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

HER2-Positive Solid Tumors

China

Search clinical trials for: EGFR/HER2 overexpression/amplification

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations